Melodia Therapeutics AG Verified listing Verified listing

  • Swiss Biotech Association
    Not a member

Melodia Therapeutics is advancing a next-generation DPP1 inhibitor to transform the treatment of severe neutrophil-driven inflammatory diseases.

Location
Additional address info
  • c/o Walder Wyss AG
Canton
Facts & figures
  • Type of organization
    Private company
  • Year of foundation
    2024
  • Number of employees in Switzerland
    1-9
Key business

You may also be interested in